|Description||Ambrisentan, a highly selective antagonist of the endothelin-1 type A receptor with IC50 of 18 nM, is indicated for the treatment of pulmonary arterial hypertension (PAH).|
Darusentan is a selective endothelin-1 receptor A inhibitor. Darusentan is identified as the treatment of congestive heart failure, hypertension and cancers. It...
Ambrisentan, a highly selective antagonist of the endothelin-1 type A receptor with IC50 of 18 nM, is indicated for the treatment of pulmonary arterial hyperten...
IRL-2500, an indol derivative, has been found to be an endothelin B receptor antagonist that was once studied in hypertension.
BMS 182874 is an endothelin receptor antagonist used as an antihypertensive agent.
Sparsentan, also known as RE-021, BMS346567, is a dual antagonist of both angiotensin II and endothelin A receptor antagonist.
Fandosentan potassium is an endothelin A antagonist developed for the treatment of pulmonary hypertension.
Clazosentan, also called as AXV 034, Ro 61-1790 or VML 588, a novel endothelin A antagonist, improves cerebral blood flow and behavior after traumatic brain inj...
Macitentan n-butyl analogue
Macitentan n-butyl analogue is a derivative of Macitentan, which is an antagonist/blocker of endothelin receptors on blood vessels and smooth muscle.